TAFINLAR (dabrafenib) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.1

OS=Overall survival.
PFS=Progression-free survival.
ORR=Overall response rate (complete response + partial response).
AR=Adverse reaction.
References: 1. TAFINLAR [summary of product characteristics]. Novartis Pharmaceuticals Corp. 2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN guidelinesTM): Melanoma. Version 3.2015. 3. Data on file_2013N175610_00. East Hanover, NJ: Novartis Pharmaceuticals Corp. 4. Grob J-J, Demidov LV, Jouary T, et al. A landmark analysis of 3-year overall survival (OS) and follow-on therapies in BREAK-3, a phase III, randomized trial: dabrafenib vs. dacarbazine (DTIC) in patients (pts) with BRAF V600E mutation-positive metastatic melanoma. Poster presented at: Society for Melanoma Research (SMR) 2014 Congress; 13-16 November 2014; Zürich, Switzerland.